Last $2.09 USD
Change Today +0.32 / 18.08%
Volume 3.4M
NVIV On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$1.79
Previous Close
$1.77
Day High
$2.17
Day Low
$1.77
52 Week High
02/27/14 - $2.67
52 Week Low
09/10/14 - $0.47
Market Cap
196.1M
Average Volume 10 Days
1.6M
EPS TTM
$-0.16
Shares Outstanding
93.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a development stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injuries (SCI). The company is developing a biocompatible Neuro-Spinal Scaffold to treat acute SCI; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Children’s Medical Center Corporation and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

45 Employees
Last Reported Date: 03/17/14
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $1.0K
Compensation as of Fiscal Year 2013.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Holdings Corp. Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial

InVivo Therapeutics Holdings Corp. (NVIV) announced that a second subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Carolinas Medical Center, part of the Carolinas HealthCare System in Charlotte, NC. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness. This is the company's first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The Investigational Device Exemption (IDE) pilot study has been approved by the FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. Following the pilot trial, InVivo expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).

InVivo Therapeutics Holdings Corp. Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. announced a three-month update for the first subject in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in subjects with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the subject on October 14, 2014 at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ by Dr. Nicholas Theodore, Chief of Spinal Surgery. In the time between implantation and the 3-month post-injury assessment, there were no reported serious adverse events associated with the Neuro-Spinal Scaffold and the subject had progressed from a complete AIS A injury to an incomplete AIS C injury with motor, sensory, bowel, and bladder function improvements. Motor improvement from the pre-surgery assessment to the 3-month visit involved the return of active movement of the hip flexors against gravity (allowing for leg to chest motions) and palpable contractions of the knee extensors. Sensory improvement from the pre-surgery assessment to the 3-month visit involved the bilateral return of sensation to two dermatomes extending down the top of the subject’s legs and the S4-S5 dermatome. In addition, the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) exam, the Spinal Cord Independence Measure (SCIM III) exam, and additional assessments of bowel and bladder function demonstrated that between hospital discharge and the 3-month visit, the subject has regained bowel function and improved bladder function. The data from the first subject were obtained and calculated in accordance with the ISNCSCI, the standard examination used to determine motor and sensory impairment and severity of a spinal cord injury.

InVivo Therapeutics Holdings Corp. Announces Reopening of Enrollment for Ongoing Pilot Trial

InVivo Therapeutics Holdings Corp. announced the reopening of subject enrollment for the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. To date, there have been no reported serious safety events with the study’s first subject, and InVivo has been cleared by the Data Safety Monitoring Board (DSMB) to move forward with the study. As specified in the study protocol, the DSMB is a committee of independent clinical research experts charged with examining the safety data accumulated during the trial. This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $2.09 USD +0.32

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.